Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
That's lower than the 7.1% discontinuation rate seen with semaglutide 2.4 mg in the STEP trials, suggesting tirzepatide is better tolerated at maximum doses despite the higher absolute milligram amount
However, Byetta and its extended-release version Bydureon BCise were discontinued in 2024
Side effects from earlier stages usually diminish or disappear
Novo Nordisks STEER study shows semaglutide 2.4 mg reduces risk of heart attack, stroke, and death by 57% compared with tirzepatide in patients with overweight or obesity and cardiovascular diseasereinforcing that CV benefits are molecule-specific, not class-wide
US$ 26.50
US$ 25.94
US$ 26.67
